Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

3.82 4.09

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.65

Max

3.85

Galvenie mērījumi
By Trading Economics
Ienākumi	-42M -78M
EPS	-0.59
Darbinieki	106
EBITDA	-42M -77M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+139.95% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 6. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	20M 351M
Iepriekšējā atvēršanas cena	-0.27
Iepriekšējā slēgšanas cena	3.82

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 19. aug. 23:56 UTC

News

Wayfair shares rise in after-market hours after Rosenblatt analyst Scott Devitt initiated coverage with a Buy rating and a price target of $125.00.

2026. g. 19. aug. 23:56 UTC

Peloton Interactive Inc shares are lower in after-market hours with no specific news to explain the decline. The stock remains below its 20-day moving average.

2026. g. 19. aug. 23:56 UTC

Shares of Nova Ltd. rose in after-market trading, despite earlier fluctuations and remaining below its 20-day moving average.

2026. g. 19. aug. 23:56 UTC

Certara Inc. shares are lower in after-hours trading, showing slight declines since Wednesday's close while remaining above the 20-day moving average.

2026. g. 19. aug. 23:56 UTC

CareDx Inc shares are higher in after-market hours, remaining above their 20-day moving average. No specific news was identified to explain the movement.

2026. g. 19. aug. 23:56 UTC

Correlated Moves

Pinnacle West Capital shares are modestly higher in after-market trading, tracking a similar rise in PG&E Corp, indicating potential market correlation.

2026. g. 19. aug. 23:56 UTC

Pentair PLC shares are lower in after-market trading, reflecting routine activity and slight declines since Wednesday's close. The price remains near the one-month midpoint.

2026. g. 19. aug. 23:56 UTC

Best Buy Co Inc shares are higher in after-market trading, fluctuating slightly while remaining above their 20-day moving average. No specific news was identified.

2026. g. 19. aug. 23:56 UTC

Charles River Laboratories shares are higher in after-market trading, reaching a notable increase since Wednesday's close and positioning near the upper end of its one-month range.

2026. g. 19. aug. 23:56 UTC

Quest Diagnostics Inc shares are higher in after-market hours, continuing a trend of four consecutive sessions finishing above their 20-day moving average.

2026. g. 19. aug. 23:56 UTC

GSI Technology Inc's shares are higher in after-market trading, despite a recent decline and ongoing weakness below the 20-day moving average.

2026. g. 19. aug. 23:56 UTC

Invesco DB Agriculture Fund is higher in after-market trading, reflecting a notable upward move since Wednesday's close and trading near its one-month range.

2026. g. 19. aug. 23:56 UTC

CF Industries remains roughly flat in after-market hours, trading near the middle of its one-month range and slightly below its 20-day moving average.

2026. g. 19. aug. 23:56 UTC

Apollo Global Management shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

2026. g. 19. aug. 23:56 UTC

Ares Capital Corp shares are higher in after-market trading, reflecting a generally positive performance backdrop. The stock remains above its 20-day moving average.

2026. g. 19. aug. 23:56 UTC

Huntington Bancshares Inc shares are higher in after-market trading, despite no specific news. The stock remains below its 20-day moving average.

2026. g. 19. aug. 23:56 UTC

FactSet Research Systems is trading lower in after-market hours, reflecting a decline since Wednesday's close, with no specific news identified for the movement.

2026. g. 19. aug. 23:56 UTC

Shoals Technologies Group Inc is trading lower in after-market hours, continuing a downward trend without any specific news to explain the movement.

2026. g. 19. aug. 23:56 UTC

News

Social Media

Cogent Communications is facing a class action lawsuit over alleged false statements, contributing to a decline in shares during after-market hours.

2026. g. 19. aug. 23:52 UTC

News

Correlated Moves

Cohen & Steers Inc. shares are lower in after-market trading, continuing a trend of five consecutive daily declines. The fund declared a monthly dividend of $0.126 per share.

2026. g. 19. aug. 23:52 UTC

Progressive Corp shares are higher in after-market hours, reflecting a modest gain since Wednesday's close. The stock remains above its 20-day moving average.

2026. g. 19. aug. 23:51 UTC

Doximity Inc shares are lower in after-market trading, with no specific news identified for the decline. The stock remains above its 20-day moving average.

2026. g. 19. aug. 23:51 UTC

Peabody Energy shares are lower in after-market trading, reversing an earlier gain. The stock remains above its 20-day moving average.

2026. g. 19. aug. 23:51 UTC

Patria Investments Ltd is trading higher in after-market hours, reaching 2.45% above Wednesday's close and showing strong momentum above its 20-day moving average.

2026. g. 19. aug. 23:51 UTC

Workday Inc. shares are higher in after-market trading, continuing a month-long upward trend and remaining above the 20-day moving average.

2026. g. 19. aug. 23:51 UTC

Pinterest Inc. shares moved lower in after-market trading, retracing earlier gains and remaining below their 20-day moving average.

2026. g. 19. aug. 23:51 UTC

Kilroy Realty Corp shares are lower in after-market trading, continuing a decline since Wednesday's close and positioned below its 20-day moving average.

2026. g. 19. aug. 23:51 UTC

Take-Two Interactive shares are higher in after-market hours, recovering from earlier lows. No specific news was identified to explain the price movement.

2026. g. 19. aug. 23:51 UTC

News

Biomarin Pharmaceutical Inc shares are lower in after-market hours amid a broader Biotechnology sector decline, despite a recent $275 million acquisition of Alesta Therapeutics.

2026. g. 19. aug. 23:51 UTC

Mixed trading in European equities as Eurozone inflation rises to 2.9% and German Bund yields hit a 12-year high amid geopolitical tensions.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

139.95% augšup

Prognoze 12 mēnešiem

Vidējais 8.83 USD 139.95%

Augstākais 11 USD

Zemākais 5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.